Galectin Therapeutics
GALT· Manufacturing· Fiscal year ends in December
No proxy on file names the CEO of Galectin Therapeutics.
Executives3
See all- 1Joel LewisFY2022
- 2Jack W. CallicuttFY2022
- 3Khurram JamilNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allGalectin Therapeutics paid its 3 named executives $2.3M in total in FY2022 (Dec).
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Galectin Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Kevin D. FreemanDirector · 14 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive
- Elissa J. Schwartz, Ph.D.Director · 8 yr on the boardIndependentDirectors, Nominees and Named Executive Officers, Nominating and Corporate Governance—Paid as an executive
- Kary EldredDirector · 7 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
No new filings about this company in the feed.
Filings6
See all| Proxy statement | DEF 14A | Oct 13, 2026 | FY2025 |
| Annual report | 10-K | Mar 31, 2026 | FY2025 |
| Proxy statement | DEF 14A | Oct 22, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Dec 3, 2024 | FY2023 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
